Other
Korean Institute of Tuberculosis
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 2
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 2(1)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT02619994Phase 2Completed
Treatment Shortening of MDR-TB Using Existing and New Drugs
Role: collaborator
NCT04485156Phase 3Not Yet Recruiting
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
Role: collaborator
NCT03934034Not Yet Recruiting
A Prospective Registry For Patients With Non-Tuberculous Mycobacterial (NTM) Pulmonary Disease in Korea.
Role: collaborator
All 3 trials loaded